Carbylan Therapeutics (CBYL) Misses Q2 EPS by 16c

Carbylan Therapeutics (NASDAQ: CBYL) reported Q2 EPS of ($0.37), $0.16 worse than the analyst estimate of ($0.21).

For earnings history and earnings-related data on Carbylan Therapeutics (CBYL) click here.

You May Also Be Interested In

• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
• Helix and Hornbeck complete all-stock merger, form new NYSE: HOS
• Humana reaffirms 2026 earnings guidance ahead of investor meetings